The study focuses on the identification and evaluation of a compound,
LCB03-0110, that exhibits potent inhibition of angiogenesis, a process critical for
tumor growth and metastasis. This compound targets key signaling pathways involving
Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) and the
Janus kinase (JAK)/
Signal Transducer and Activator of Transcription 3 (STAT3) signaling.
LCB03-0110 was found to inhibit VEGFR-2, JAK/STAT3 signaling in both primary cultured human endothelial cells and cancer cells. The compound's mechanism of action was elucidated through in vitro kinase assays and molecular modeling, revealing that it binds preferentially at the ATP-binding site of VEGFR-2,
c-SRC, and TIE-2 kinases, thereby inhibiting their activity.
The compound effectively suppressed
hypoxia-induced
HIF/STAT3 and signaling pathways triggered by
EGF or
angiopoietin. It also reduced
VEGF-induced endothelial cell proliferation, viability, migration, and capillary-like tube formation. Furthermore, LCB03-0110 demonstrated the ability to inhibit endothelial cell sprouting in the rat aorta and new blood vessel formation in the mouse Matrigel plug assay.
In addition to its effects on angiogenesis, LCB03-0110 also suppressed pulmonary metastasis and tumor xenograft growth in mice. These findings indicate that LCB03-0110 is a promising candidate for the development of a small molecule therapeutic that can block angiogenesis driven by the aberrant activation of VEGFR-2 and JAK/STAT3 signaling pathways.
How to Use Synapse Database to Search and Analyze Translational Medicine Data?
The transational medicine section of the Synapse database supports searches based on fields such as drug, target, and indication, covering the T0-T3 stages of translation. Additionally, it offers a historical conference search function as well as filtering options, view modes, translation services, and highlights summaries, providing you with a unique search experience.

Taking obesity as an example, select "obesity" under the indication category and click search to enter the Translational Medicine results list page. By clicking on the title, you can directly navigate to the original page.

By clicking the analysis button, you can observe that GLP-1R treatment for obesity has gained significant attention over the past three years, with preclinical research still ongoing in 2023. Additionally, there are emerging potential targets, such as GDF15, among others.

Click on the image below to go directly to the Translational Medicine search interface.
